Hypoglycemia : For those also using insulin or other diabetes medications, semaglutide can increase the risk of low blood sugar
This is also associated with the retarded gastric emptying and appetite control in research studies
So far, deaths that have occurred during retatrutide trials have been assessed and found to be unrelated to treatment
Semaglutide, by contrast, activates glucagon-like peptide-1 receptors in the brain and pancreas, directly reducing hunger, slowing gastric emptying, and improving blood sugar control
Individuals most likely to benefit include: Those with pernicious anemia People with gastrointestinal disorders (e.g., Crohns disease, celiac disease, chronic gastritis) Patients following bariatric (weight loss) surgery Older adults with absorption difficulties Strict vegetarians or vegans at risk for deficiency People taking medications that can decrease vitamin B12 levels Laboratory testing usually confirms B12 deficiency before starting injections